Sample and Data Usage Committee

The Sample and Data Usage Committee reviews newly submitted project proposals in order to analyze its alignment with the aim of the project which originated the sample or data collection requested, its technical/ ethical viability, and its potential scientific impact. The Sample and Data Usage Committee is composed by the Head of Translational Operations, the Head of Clinical Operations, the Head of the Data Management Center, the General Manager of EF CLIF, and the EF CLIF Director. The Principal Investigator(s) of the project(s) samples and data are requested from also contribute to the evaluation and decision making process of granting access to datasets and samples of interest available in the EF CLIF databases and biobank.

Membership of the Sample and Data Usage Committee

PositionName / AffiliationYear appointment
Ex officio (Head of Translational Operations)Joan Clària, PhD
EF CLIF, Spain
2022
Ex officio (Head of Clinical Operations)Javier Fernández, PhD
EF CLIF, Spain
2022
Ex officio (Head of the Data Management Center)Cristina Sánchez-Garrido
EF CLIF, Spain
2022
Ex officio (General Manager)Anna Bosch, PhD
EF CLIF, Spain
2022
Ex officio (Director)Richard Moreau, MD
EF CLIF, Spain
2022
Co-opted membersAlberto Farias, MD, PhD
Hospital das Clínicas, Brazil
2022
Thierry Gustot, MD, PhD
CUB Hôpital Erasme, Belgium
2022
Rajiv Jalan, MD, PhD
University College London, UK
2022
Gautam Mehta, MD, PhD
University College London, UK
2022
Pierre-Emmanuel Rautou, MD, PhD
Hôpital Beaujon AP-HP, France
2022
Jonel Trebicka, MD, PhD
University Hospital Münster, Germany
2022

Recently approved ancillary studies

This page lists independent investigator-led projects approved by the Samples and Data Usage Committee to date by fiscal year.

Code: SDUC_2026_302_002
Juan Nieto, Centro Nacional de Análisis Genómico, Spain
ACLF atlas

Code: SDUC_2026_302_003
Florent Artru, CHU Rennes, France
Re-examining the CANONIC, PREDICT and ACLARA metabolomic datasets from the perspective of fatty acid oxidation overflow and the ω-oxidation pathway


Code: SDUC_2026_302_004
Rudolphe Anty, CHU de Nice, France
Lactate-to-glucose ratio as a novel prognostic marker in acute-on-chronic liver failure

Code: SDUC_2026_312_001
Josefin Soppert, RWTH Aachen University, Germany
Inflammation profiles in patients with ACLF

Code: SDUC_2026_314_001
Maria Papp, University of Debrecen, Hungary
Markers gut barrier damage and prognosis

Code: SDUC_2026_325_001
Marina Berenguer, La Fe Research Institute, Spain
Acute-on-chronic liver failure grades 2 and 3 in women: Prognostic implications and access to liver transplantation in the CHANCE cohort

Code: SDUC_2026_325_003
Dean Karvellas, University of Alberta, Canada
Impact of preoperative respiratory failure/acute lung injury on post-transplant outcomes in patients with acute-on-chronic liver failure

Code: SDUC_2026_325_004
Rajiv Jalan, University College London, UK
Defining the histopathology of acute-on-chronic liver failure using liver biopsies from the CHANCE study

Code: SDUC_2025_302_002
Marta Tonon, University of Padova, Italy
Sex-related differences in AD and ACLF

Code: SDUC_2025_302_003
Florent Artru, CHU Rennes, France
Impact of primary cause of admission to intensive care. Medicine in patients with ACLF

Code: SDUC_2025_302_004
Laure Elkrief, CHU Tours, France
Investigating the 1-year of patients discharged from Hospital after admission to ICU in a context of ACLF

Code: SDUC_2025_302_004
Rudolph Stauber, Medical University of Graz, Austria
A HDL-based cirrhosis risk score improves the prediction of short-term mortality in acutely decompensated cirrhosis

Code: SDUC_2025_323_001
David Gómez-Cabrero, Navarrabiomed, Spain
Epigenetic signatures of acute decompensation in cirrhosis: DNA methylation and disease progression

Code: SDUC_2025_325_001
Cornelius Engelmann, Charité – Universitätsmedizin Berlin, Germany
Body composition analysis as a predictor of poor outcomes in patients with ACLF

Code: SDUC_2024_302_003
Maria Pilar Ballester Ferré, Hospital Clínico Universitario de Valencia, Spain
Factors associated with progression, resolution and mortality of patients with overt hepatic encephalopathy

Code: SDUC_2024_302_004
Emmanuel Weiss, Hôpital Beaujon, France
Clonal hematopoiesis as a predictor of the clinical course of patients with acutely decompensated cirrhosis

Code: SDUC_2024_312_003
Thomas Reiberger, Medical University of Vienna, Austria
The vasopressin biomarker copeptin is linked to systemic inflammation and refines prognostication in decompensated cirrhosis

Code: SDUC_2024_323_001
Joan Clària, Hospital Clínic de Barcelona – IDIBAPS, Spain
Blood multiomics reveal a dysregulated lipid mediator-mitochondrial network associated with the outcome of advanced cirrhosis

Code: SDUC_2023_302_001
Rosa Martin Mateos, Instituto Ramón y Cajal de Investigación Sanitaria, Spain
Prognostic value of neutrophil-to-lymphocyte ratio as a marker of immune dysfunction in ACLF

Code: SDUC_2023_302_003
Florian van Bömmel, University of Leipzig, Germany
Detection of 1,3-beta-D-glucan as an independent predictor of mortality in patients with acute on chronic liver failure


Code: SDUC_2023_302_005
Eric Trépo, Université Libre de Bruxelles, Belgium
Evaluating the impact of cardiopulmonary complications in cirrhosis and ACLF: Hepatopulmonary syndrome, portopulmonary hypertension and cirrhotic cardiomyopathy / diastolic dysfunction

Code: SDUC_2023_302_006
Eric Trépo, Université Libre de Bruxelles, Belgium
Decoding prognostic trajectories in decompensated cirrhosis without acute-on-chronic liver failure: A machine learning approach

Code: SDUC_2023_302_009
Schalk van der Merwe, KU Leuven, Belgium
Distinct immunometabolic signatures in circulating immune cells define disease outcomes in acute-on-chronic liver failure

Code: SDUC_2023_302_011
Eric Trépo, Université Libre de Bruxelles, Belgium
Genome-wide association study identifies EPHA2 as a new susceptibility locus for
hepatocellular carcinoma in patients with alcohol-related liver disease

Code: SDUC_2023_302_012
Philippe Meersseman, KU Leuven, Belgium
[Title not available]

Code: SDUC_2022_302_004
Alastair O’Brien, University College London, UK
Physiological network mapping as a predictor of mortality, acute-on-chronic liver failure, and renal failure in patients with acute decompensation of cirrhosis

Code: SDUC_2022_302_005
Xavier Verhelst, Ghent University, Belgium
Development and outcome of ACLF in patients with autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis compared to patients with non-autoimmune chronic liver disease: Analysis of a multicentric international cohort


Code: SDUC_2022_323_001
Johanna Reissing, RWTH Aachen University, Germany
Multi-omics integration reveals regulatory mechanisms and clinical relevance of circulating miRNAs in acute-on-chronic liver failure

Code: SDUC_2022_323_002
Pierre-Emmanuel Rautou, Hôpital Beaujon AP-HP, France
Extracellular vesicles for prediction of outcomes in patients with acutely decompensated cirrhosis

Code: SDUC_2022_323_004
David Gomez-Cabrero, Navarrabiomed, Spain
A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis

Code: SDUC_2022_330_001
Cornelius Engelmann, Charité – Universitätsmedizin Berlin, Germany
Alcohol- and infection-associated ACLF define distinct phenotypes with differential biomarker utility